Antipseudomonal Versus Narrow-Spectrum Agents for the Treatment of Community-Onset Intra-abdominal Infections

被引:0
|
作者
Worden, Lacy J. [1 ]
Dumkow, Lisa E. [1 ,2 ]
VanLangen, Kali M. [1 ,3 ]
Beuschel, Thomas S. [1 ]
Jameson, Andrew P. [1 ,2 ,4 ]
机构
[1] Mercy Hlth St Marys, Dept Pharm, Grand Rapids, MI 49503 USA
[2] Mercy Hlth St Marys, Div Infect Dis, Grand Rapids, MI 49503 USA
[3] Ferris State Univ, Coll Pharm, Big Rapids, MI USA
[4] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2021年 / 8卷 / 11期
关键词
antimicrobial resistance; antipseudomonal; appendicitis; diverticulitis; intra-abdominal infections; RESISTANCE; CHILDREN;
D O I
10.1093/ofid/ofab514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Antipseudomonal antibiotics are often used to treat community-acquired intra-abdominal infections (CA-IAIs) despite common causative pathogens being susceptible to more narrow-spectrum agents. The purpose of this study was to compare treatment-associated complications in adult patients treated for CA-IAI with antipseudomonal versus narrow-spectrum regimens. Methods. This retrospective cohort study included patients >18 years admitted for CA-IAI treated with antibiotics. The primary objective of this study was to compare 90-day treatment-associated complications between patients treated empirically with antipseudomonal versus narrow-spectrum regimens. Secondary objectives were to compare infection and treatment characteristics along with patient outcomes. Subgroup analyses were planned to compare outcomes of patients with low-risk and high-risk CA-IAIs and patients requiring surgical intervention versus medically managed. Results. A total of 350 patients were included: antipseudomonal, n = 204; narrow spectrum, n = 146. There were no differences in 90-day treatment-associated complications between groups (antipseudomonal 15.1% vs narrow spectrum 11.3%, P = .296). In addition, no differences were observed in hospital length of stay, 90-day readmission, Clostridiodes difficile, or mortality. In multivariate logistic regression, treatment with a narrow-spectrum regimen (odds ratio [OR], 0.75; 95% confidence interval, 0.39-1.45) was not independently associated with the primary outcome. No differences were observed in 90-day treatment-associated complications for (1) patients with low-risk (antipseudomonal 15% vs narrow spectrum 9.6%, P = .154) or high-risk CA-IAI (antipseudomonal 15.8% vs narrow spectrum 22.2%, P = .588) or (2) those who were surgically (antipseudomonal 8.5% vs narrow spectrum 9.2%, P = .877) or medically managed (antipseudomonal 23.1 vs narrow spectrum 14.5, P = .178). Conclusions. Treatment-associated complications were similar among patients treated with antipseudomonal and narrow-spectrum antibiotics. Antipseudomonal therapy is likely unnecessary for most patients with CA-IAI.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] EFFICACY OF DACTIMICIN IN THE TREATMENT OF EXPERIMENTALLY INDUCED INTRA-ABDOMINAL INFECTIONS
    NORD, CE
    LAHNBORG, G
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1989, 15 (03) : 115 - 118
  • [33] Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections
    Maseda, Emilio
    Aguilar, Lorenzo
    Gimenez, Maria-Jose
    Gilsanz, Fernando
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (11) : 1311 - 1324
  • [34] Cost of care for inpatients with community-acquired intra-abdominal infections
    Cattan, P
    Yin, DD
    Sarfati, E
    Lyu, R
    de Zelicourt, M
    Fagnani, F
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (11) : 787 - 793
  • [35] Systematic review: fluoroquinolones for the treatment of intra-abdominal surgical infections
    Falagas, M. E.
    Matthaiou, D. K.
    Bliziotis, I. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (02) : 123 - 131
  • [36] ANTIMICROBIAL STEWARDSHIP IMPACT ON THE TREATMENT OF INTRA-ABDOMINAL INFECTIONS IN THE SICU
    Peterson, Meghan
    Flynn, Jade
    Smith, Michael
    Rumbaugh, Kelli
    CRITICAL CARE MEDICINE, 2025, 53 (01)
  • [37] Cost of Care for Inpatients with Community-Acquired Intra-Abdominal Infections
    P. Cattan
    D. Yin
    E. Sarfati
    R. Lyu
    M. de Zelicourt
    F. Fagnani
    European Journal of Clinical Microbiology and Infectious Diseases , 2002, 21 : 787 - 793
  • [38] MOXALACTAM IN THE TREATMENT OF INTRA-ABDOMINAL SEPSIS AND OTHER SURGICAL INFECTIONS
    BUSUTTIL, RW
    MCGRATTAN, MA
    WINSTON, DJ
    REVIEWS OF INFECTIOUS DISEASES, 1982, 4 : S676 - S682
  • [39] Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections
    Madan, AK
    CLINICAL THERAPEUTICS, 2004, 26 (10) : 1564 - 1577
  • [40] Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections
    Buckman, Sara A.
    Krekel, Tamara
    Muller, Anouk E.
    Mazuski, John E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (17) : 2341 - 2349